<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939900</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446HKR08T</org_study_id>
    <nct_id>NCT00939900</nct_id>
  </id_info>
  <brief_title>Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head</brief_title>
  <acronym>EZAPCOFH</acronym>
  <official_title>Multicenter, Open-labeled, Randomized Clinical Trial to Determine the Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Korea Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effect of zoledronic acid over 2 years in preventing
      early collapse and progression of joint dome depression (≥ 2 mm by X-ray) of the femoral head
      in patients with large (&gt; 30%: criteria according to Kim et al) nontraumatic osteonecrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Until now, the best treatment option in early (precollapse) large osteonecrosis femoral head
      is vascularizing fibular graft. However, it requires high microsurgical technique. Also it
      needs very long operation time (3-6hours), and morbidity associated with surgery is not low.
      In early stage osteonecrosis, osteoclasts are activated and resorb the necrotic portion of
      bone and osteoblasts are followed to lay down new bone. This process can weaken the bone
      function to support loading and can lead to collapse of bone. Bisphophonate can inhibit this
      osteoclastic bone resorption and enhance osteoblastic new bone formation. Recently, everyday
      oral intake of alendronate with vitamin D and calcium had a high success rate to prevent the
      collapse and decrease of hip joint pain in a short-term follow-up. However, the compliance or
      adherence to everyday oral intake is questionable. Moreover, the exact comparison based on
      MRI according to various classifications is not available currently. There is no report about
      the effect of zoledronic acid to prevent early collapse and progression of joint dome
      depression (≥2 mm by X-ray) of the early stage large nontraumatic osteonecrosis of the
      femoral head or its effect on MRI signal change after infusion of zoledronic acid in
      noncollapsed cases (estimated about 30% of cases) The investigators need a controlled
      randomized multicenter interventional study about the efficacy of bisphophonates in the
      treatment of ONFH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Femoral Head Collapse Within 24 Months</measure>
    <time_frame>Measurements were done at 6, 12, 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collpase Rate of Femoral Head</measure>
    <time_frame>Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HHS (Harris Hip Scores), WOMAC Score, SF-36</measure>
    <time_frame>Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Collapse of Femoral Head</measure>
    <time_frame>Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Total Arthroplasty or Joint Preserving Surgery</measure>
    <time_frame>Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Avascular Necrosis of Femoral Head</condition>
  <arm_group>
    <arm_group_label>aclasta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aclasta group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid (aclasta)</intervention_name>
    <description>Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period</description>
    <arm_group_label>aclasta</arm_group_label>
    <other_name>aclasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who agree to clinical trial

          -  Patient who are more than 18 years of age

          -  Osteonecrosis of the femoral head

          -  Steinberg stage I, II non traumatic osteonecrosis of femoral head

          -  Necrotic area of &gt; 30% (HJ Kim et al )

          -  JIC (Japanese Investigation Committee): C1 or C2 lateral lesion (by X-ray or MRI)

        Exclusion Criteria:

          -  Patients who are pregnant (patients who are of child bearing potential who are not
             practicing a reliable contraceptive method (oral, subcutaneous, mechanical, or
             surgical contraception)

          -  Patients who have contraindicated condition to zoledronic acid such as chronic renal
             failure (calculated creatinine clearance less than 35.0 ml/min), severe heart disease
             such as atrial fibrillation, sensitive to bisphosphonates and hypocalcemia (serum
             calcium less than 8 mg/dl or 2.0 mmol/L)

          -  Patients who have collapsed lesion including subchonral fracture

          -  Patients who have multiple lesion of osteonecrosis of femoral head

          -  Patients who received other kinds of bisphophonates or anabolic agents before
             zoledronic acid use

          -  Patients with any medical or psychiatric condition which, in the Investigator's
             opinion would preclude the participant from adhering to the Protocol or completing the
             trial per protocol

          -  Patients who are considered potentially unreliable and patients who may not reliably
             attend study visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Hoi Koo, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul national University Bundang Hospital</name>
      <address>
        <city>Seongnam-Si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <results_first_submitted>May 18, 2015</results_first_submitted>
  <results_first_submitted_qc>June 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2015</results_first_posted>
  <last_update_submitted>June 7, 2015</last_update_submitted>
  <last_update_submitted_qc>June 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Kyung-Hoi Koo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>avascular necrosis of femoral head</keyword>
  <keyword>bisphosphonate</keyword>
  <keyword>collapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aclasta</title>
          <description>aclasta group
zoledronic acid (aclasta): Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>control group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aclasta</title>
          <description>aclasta group
zoledronic acid (aclasta): Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>control group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="11.8"/>
                    <measurement group_id="B2" value="45.2" spread="11.6"/>
                    <measurement group_id="B3" value="44.5" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Femoral Head Collapse Within 24 Months</title>
        <time_frame>Measurements were done at 6, 12, 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aclasta</title>
            <description>aclasta group
zoledronic acid (aclasta): Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>control group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Femoral Head Collapse Within 24 Months</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Collpase Rate of Femoral Head</title>
        <time_frame>Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of HHS (Harris Hip Scores), WOMAC Score, SF-36</title>
        <time_frame>Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Collapse of Femoral Head</title>
        <time_frame>Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Total Arthroplasty or Joint Preserving Surgery</title>
        <time_frame>Measurement will be done at 0m, 3m, 6m, 9m, 12m, 18m, 24m)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aclasta</title>
          <description>aclasta group
zoledronic acid (aclasta): Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>control group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor</name_or_title>
      <organization>SeoulNUBH</organization>
      <phone>82317877194</phone>
      <email>khkoo@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

